103 related articles for article (PubMed ID: 15747430)
1. Pill burden reduced for saquinavir.
AIDS Patient Care STDS; 2005 Feb; 19(2):128. PubMed ID: 15747430
[No Abstract] [Full Text] [Related]
2. Searching for the right dose of ritonavir-saquinavir.
TreatmentUpdate; 2001 Sep; 13(5):3. PubMed ID: 11768860
[No Abstract] [Full Text] [Related]
3. Boosted saquinavir approved.
AIDS Patient Care STDS; 2004 Mar; 18(3):183. PubMed ID: 15112642
[No Abstract] [Full Text] [Related]
4. [Ritonavir/Saqinavir: dual protease inhibitor combination. Salvage therapy].
MMW Fortschr Med; 2000; 142(3 Suppl):41. PubMed ID: 11012293
[No Abstract] [Full Text] [Related]
5. [New formulation--fewer tablets--optimal effect].
Krankenpfl J; 2005; 43(7-10):249. PubMed ID: 16515318
[No Abstract] [Full Text] [Related]
6. Combo approved for HIV treatment.
Nurse Pract; 2004 Mar; 29(3):40. PubMed ID: 15052701
[No Abstract] [Full Text] [Related]
7. Combination suppresses HIV RNA within the central nervous system.
AIDS Patient Care STDS; 1998 Jan; 12(1):65. PubMed ID: 11361893
[No Abstract] [Full Text] [Related]
8. Saquinavir once daily.
TreatmentUpdate; 2002; 14(4):4. PubMed ID: 12064314
[No Abstract] [Full Text] [Related]
9. From grapefruit juice to ritonavir.
TreatmentUpdate; 2001; 12(12):5-6. PubMed ID: 11570093
[No Abstract] [Full Text] [Related]
10. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.
van der Lugt J; Colbers A; Molto J; Hawkins D; van der Ende M; Vogel M; Wyen C; Schutz M; Koopmans P; Ruxrungtham K; Richter C; Burger D;
Antivir Ther; 2009; 14(3):443-50. PubMed ID: 19474478
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
[TBL] [Abstract][Full Text] [Related]
13. Saquinavir/Ritonavir: its evolution and current treatment role.
O'Brien WA
AIDS Read; 2006 Jan; 16(1):38-44; discussion 43. PubMed ID: 16433471
[TBL] [Abstract][Full Text] [Related]
14. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
[TBL] [Abstract][Full Text] [Related]
15. Saquinavir switch study stopped.
Treat Rev; 1997 Apr; (No 24):6. PubMed ID: 11364285
[TBL] [Abstract][Full Text] [Related]
16. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
17. New gel formulation for saquinavir.
AIDS Patient Care STDS; 1997 Oct; 11(5):373-4. PubMed ID: 11361823
[No Abstract] [Full Text] [Related]
18. Twice daily saquinavir.
AIDS Patient Care STDS; 1999 May; 13(5):307. PubMed ID: 10356812
[No Abstract] [Full Text] [Related]
19. Dose reduction effective in alleviating symptoms of saquinavir toxicity.
Stephan C; Carlebach A; Rottmann C; Haberl A; Dauer B; von Hentig N; Kurowski M; Staszewski S
Int J STD AIDS; 2007 Feb; 18(2):81-4. PubMed ID: 17331276
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J;
Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
